Precise ablation therapy for primary liver cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YAN Yuzheng , XIAO Sijie ,  MA Kuansheng

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Army Medical University , Chongqing 400038, P. R. China;

Corresponding?author：

MA Kuansheng, Email: kuanshengma@outlook.com

Keywords：

primary liver cancer; radiofrequency ablation; precise therapy

DOI：

10.7507/1007-9424.202410011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In 2022, there were 367.7 thousands new cases and 316.5 thousands deaths of primary liver cancer in China. Radiofrequency ablation (RFA) is one of the radical treatments for liver cancer. It has the characteristics of definite curative effect, minimal invasion and low cost. In patients with early liver cancer, the curative effect is similar to surgical resection. The concept and practice of precision surgery provide new ideas for improving the efficacy of RFA. Based on the RFA treatment experience of more than ten thousand cases, the author’s team has carried out research on the precise ablation treatment of primary liver cancer. Now, the author will combine the existing literature and our team’s experience to discuss the application and prospect of the precise surgery concept in RFA treatment.

Citation： YAN Yuzheng, XIAO Sijie, MA Kuansheng. Precise ablation therapy for primary liver cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(12): 1430-1433. doi: 10.7507/1007-9424.202410011 Copy

1.	中華人民共和國國家衛生健康委員會醫政司. 原發性肝癌診療指南(2024年版). 中華消化外科雜志, 2024, 23(4): 429-478.
2.	馮凱, 馬寬生, 別平. 射頻消融在肝細胞肝癌根治性治療中的臨床價值. 中國普外基礎與臨床雜志, 2014, 21(2): 150-155.
3.	Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology, 2018, 287(2): 461-472.
4.	董家鴻, 張寧. 精準外科. 中華外科雜志, 2015, 53(5): 321-323.
5.	樊嘉, 高強. 肝癌診療新進展: 指南引領規范創新賦能精準. 中華消化外科雜志, 2024, 23(2): 197-203.
6.	Li C, Wang Q, Zou M, et al. A radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Front Oncol, 2023, 13: 1164739. doi: 10.3389/fonc.2023.1164739.
7.	蔣涵羽, 陳衛霞. 淺析肝臟影像報告及數據系統在肝細胞癌診治中的關鍵應用及挑戰. 中國普外基礎與臨床雜志, 2024, 31(3): 272-277.
8.	Jiang YQ, Wang ZX, Deng YN, et al. Efficacy of hepatic resection vs. radiofrequency ablation for patients with very-early-stage or early-stage hepatocellular carcinoma: A population-based study with stratification by age and tumor size. Front Oncol, 2019, 9: 113. doi: 10.3389/fonc.2019.00113.
9.	Zhang K, Jiang L, Jia Z, et al. Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices. Dig Dis Sci, 2015, 60(5): 1490-1501.
10.	Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 262-276.
11.	盛思滿, 陳闖, 陳小宇, 等. 釓塞酸二鈉增強磁共振成像在肝細胞癌大體形態分型中的應用價值. 中國普外基礎與臨床雜志, 2023, 30(7): 814-819.
12.	Liu J, Guo Y, Sun Y, et al. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma. Int J Hyperthermia, 2024, 41(1): 2316097. doi: 10.1080/02656736.2024.2316097.
13.	Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol, 2016, 64(3): 594-600.
14.	楊世忠, 馮曉彬, 董家鴻. 精準外科理念指導下的肝癌外科治療. 精準醫學雜志, 2018, 33(3): 189-192,196.
15.	李璟寰, 王艷紅. 射頻消融治療肝癌研究概況. 中華臨床醫師雜志(電子版), 2013, 7(8): 3526-3530.
16.	Ikeda K, Osaki Y, Nakanishi H, et al. Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology, 2014, 87 Suppl 1: 73-77.
17.	周儉, 樊嘉, 肖永勝. 肝細胞癌門靜脈癌栓形成機制. 實用腫瘤雜志, 2009, 24(5): 425-428.
18.	Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia, 2018, 34(6): 870-876.
19.	蔡建強, 趙宏, 陳曉. 肝癌綜合治療新格局. 中華消化外科雜志, 2024, 23(2): 204-208.
20.	Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia, 2021, 38(1): 1519-1528.
21.	Cheng AL, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 307-319.
22.	Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol, 2021, 7(1): 113-123.
23.	Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol, 2014, 109(12): 1891-1899.
24.	Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer, 2020, 9(6): 640-662.
25.	中華醫學會超聲醫學分會介入診療學組, 中國醫藥教育協會介入微創治療專委會納米刀腫瘤消融學會. 超聲引導肝癌不可逆電穿孔消融治療臨床實踐指南(2023版). 中華超聲影像學雜志, 2023, 32(12): 1013-1020.

1. 中華人民共和國國家衛生健康委員會醫政司. 原發性肝癌診療指南(2024年版). 中華消化外科雜志, 2024, 23(4): 429-478.
2. 馮凱, 馬寬生, 別平. 射頻消融在肝細胞肝癌根治性治療中的臨床價值. 中國普外基礎與臨床雜志, 2014, 21(2): 150-155.
3. Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology, 2018, 287(2): 461-472.
4. 董家鴻, 張寧. 精準外科. 中華外科雜志, 2015, 53(5): 321-323.
5. 樊嘉, 高強. 肝癌診療新進展: 指南引領規范創新賦能精準. 中華消化外科雜志, 2024, 23(2): 197-203.
6. Li C, Wang Q, Zou M, et al. A radiomics model based on preoperative gadoxetic acid-enhanced magnetic resonance imaging for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Front Oncol, 2023, 13: 1164739. doi: 10.3389/fonc.2023.1164739.
7. 蔣涵羽, 陳衛霞. 淺析肝臟影像報告及數據系統在肝細胞癌診治中的關鍵應用及挑戰. 中國普外基礎與臨床雜志, 2024, 31(3): 272-277.
8. Jiang YQ, Wang ZX, Deng YN, et al. Efficacy of hepatic resection vs. radiofrequency ablation for patients with very-early-stage or early-stage hepatocellular carcinoma: A population-based study with stratification by age and tumor size. Front Oncol, 2019, 9: 113. doi: 10.3389/fonc.2019.00113.
9. Zhang K, Jiang L, Jia Z, et al. Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices. Dig Dis Sci, 2015, 60(5): 1490-1501.
10. Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 262-276.
11. 盛思滿, 陳闖, 陳小宇, 等. 釓塞酸二鈉增強磁共振成像在肝細胞癌大體形態分型中的應用價值. 中國普外基礎與臨床雜志, 2023, 30(7): 814-819.
12. Liu J, Guo Y, Sun Y, et al. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma. Int J Hyperthermia, 2024, 41(1): 2316097. doi: 10.1080/02656736.2024.2316097.
13. Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol, 2016, 64(3): 594-600.
14. 楊世忠, 馮曉彬, 董家鴻. 精準外科理念指導下的肝癌外科治療. 精準醫學雜志, 2018, 33(3): 189-192,196.
15. 李璟寰, 王艷紅. 射頻消融治療肝癌研究概況. 中華臨床醫師雜志(電子版), 2013, 7(8): 3526-3530.
16. Ikeda K, Osaki Y, Nakanishi H, et al. Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology, 2014, 87 Suppl 1: 73-77.
17. 周儉, 樊嘉, 肖永勝. 肝細胞癌門靜脈癌栓形成機制. 實用腫瘤雜志, 2009, 24(5): 425-428.
18. Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia, 2018, 34(6): 870-876.
19. 蔡建強, 趙宏, 陳曉. 肝癌綜合治療新格局. 中華消化外科雜志, 2024, 23(2): 204-208.
20. Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia, 2021, 38(1): 1519-1528.
21. Cheng AL, Hsu C, Chan SL, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 2020, 72(2): 307-319.
22. Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol, 2021, 7(1): 113-123.
23. Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol, 2014, 109(12): 1891-1899.
24. Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer, 2020, 9(6): 640-662.
25. 中華醫學會超聲醫學分會介入診療學組, 中國醫藥教育協會介入微創治療專委會納米刀腫瘤消融學會. 超聲引導肝癌不可逆電穿孔消融治療臨床實踐指南(2023版). 中華超聲影像學雜志, 2023, 32(12): 1013-1020.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Precise ablation therapy for primary liver cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content